Khan M U, Khan S, El-Refaie S, Win Z, Rubello D, Al-Nahhas A
Department of Nuclear Medicine, Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore, Pakistan.
Eur J Surg Oncol. 2009 Jun;35(6):561-7. doi: 10.1016/j.ejso.2009.01.007. Epub 2009 Feb 7.
(68)Ga-PET imaging is showing slow but steady progress when compared to (18)F-FDG PET. The advantage of in-house preparation of (68)Ga without necessity of a cyclotron, and the new generator configuration with future possibility of freeze-dried kits would make it a promising PET agent for the future.
An exhaustive literature exploration was performed using the search engines High-Wire Press, Pubmed, Embase and library databases. Recent reviews on the subject and up-to-date studies on the topic were found that described the role of (68)Ga-PET imaging. Clinical experiences, including our own are described.
Recent resurgence in development of peptides labelled with radiometals, for diagnostic and therapeutic purposes, resulted in a new beginning for (68)Ga-PET imaging. Pre-clinical experience employing animal models and investigation of tracer kinetics/tumour uptake measurements using dynamic (68)Ga-PET have provided data regarding identification of Somatostatin receptors subtypes on many tumours. Present published experiences including our own support these and highlight current clinical utility of (68)Ga-PET imaging. (68)Ga-DOTATOC and (68)Ga-DOTANOC are the most prominent radiopharmaceuticals used nowadays.
(68)Ga-PET is employed in the management of neuroendocrine tumours and neural crest tumours (phaeochromocytoma and paraganglioma) with diagnostic and therapeutic implications where it compliments present radiologic and scintigraphic procedures. Diagnosis and radiotherapy treatment planning for meningiomas in pertinent clinical setting is another potential use of (68)Ga-PET. Limited studies have shown its utility in prostate cancer but further studies are contemplated. Therefore, current experience tends to open a new horizon for the clinical utility of (68)Ga-PET imaging in future.
与（18）F-FDG PET相比，（68）Ga-PET成像进展缓慢但稳步推进。无需回旋加速器即可在内部制备（68）Ga的优势，以及新型发生器配置和未来冻干试剂盒的可能性，使其成为未来有前景的PET显像剂。
使用High-Wire Press、PubMed、Embase等搜索引擎和图书馆数据库进行全面的文献检索。发现了近期关于该主题的综述以及最新的相关研究，这些研究描述了（68）Ga-PET成像的作用。还描述了包括我们自己的临床经验。
近期用于诊断和治疗目的的放射性金属标记肽的研发复兴，为（68）Ga-PET成像带来了新的开端。采用动物模型的临床前经验以及使用动态（68）Ga-PET对示踪剂动力学/肿瘤摄取测量的研究，提供了有关多种肿瘤上生长抑素受体亚型鉴定的数据。目前已发表的经验包括我们自己的经验，均支持这些研究，并突出了（68）Ga-PET成像当前的临床应用价值。（68）Ga-DOTATOC和（68）Ga-DOTANOC是目前最常用的放射性药物。
（68）Ga-PET用于神经内分泌肿瘤和神经嵴肿瘤（嗜铬细胞瘤和副神经节瘤）的管理，具有诊断和治疗意义，可补充现有的放射学和闪烁显像程序。在相关临床环境中，对脑膜瘤进行诊断和放射治疗计划是（68）Ga-PET的另一个潜在用途。有限的研究表明其在前列腺癌中的应用价值，但仍需进一步研究。因此，目前的经验倾向于为未来（68）Ga-PET成像的临床应用开辟新的前景。
